Implementation of a Pharmacist-led Pharmacogenomic Clinical Service
Sponsored by Tabula Rasa HealthCare
About this trial
Last updated 3 years ago
Study ID
PGX-INITIATIVE-TRHC-2020-002
Status
Withdrawn
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 3 years ago
What is this trial about?
Tabula Rasa HealthCare (TRHC), doing business as CareKinesis, is the first national pharmacy
that provides science-based medication risk identification and mitigation technologies and
services. CareKinesis utilizes medication decision support tools and pharmacists certified in
geriatrics to provide pharmacy services for various healthcare organizations including PACE
organizations (described above). Presently, CareKinesis services more than 35 PACE
organizations, including approximately 100 PACE sites, across the United States. As a
national PACE pharmacy provider since 2011, CareKinesis focuses on improving medication
regimens to reduce medication-related risks while enhancing economic, clinical and humanistic
outcomes. Pharmacist-led PGx clinical services and medication safety reviews are currently
being offered to PACE organizations under the direction of licensed healthcare prescribers by
TRHC (CareKinesis). Our aim is to extend and meticulously study PGx testing for more PACE
patients and conduct a prospective preemptive PGx study to determine feasibility of
implementation and effect on outcomes. After mutual agreement, these services may also be
extended to other organizations where TRHC provides pharmacy services, and data will be
collected with patient consent.
What are the participation requirements?
Inclusion Criteria
- Patients meeting all the following criteria will be included:
1. Patient is enrolled in a healthcare organization where TRHC provides pharmacy services during the implementation period;
2. Patient is able to understand, and provide informed consent to participate.
Exclusion Criteria
- Patients with one of the following criteria will be excluded:
1. Have taken an investigational product in the last 30 days;
2. Current use of illicit substances;
3. Any other medical, cognitive or physical abnormality, disease, or disorder that would prohibit the patient from completing study procedures in the judgement of the investigator and/or the prescriber.